Abstract. Nucleic acid-editing enzymes of the apolipoprotein B mRNA-editing enzyme (APOBEC) family have been associated with somatic mutation in cancer. However, the role of APOBEC catalytic subunit 3B (APOBEC3B) editing in the pathogenesis of base substitutions in meningiomas is unknown. In the present study, the expression of APOBEC3B was examined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analyses in five fetal and one adult human leptomeninges and 38 meningiomas. Genomic DNA was sequenced using the Illumina Tru-Seq Cancer Panel. Three meningioma primary cultures were also established and treated with cerebrospinal fluid form patients without neurological disease or platelet-derived growth factor-BB (PDGF-BB), prior to evaluation of APOBEC3B expression. By western blotting, APOBEC3B was revealed to be present in 100% of the fetal leptomeninges, and in 88% of World Health Organization grade I, 100% of grade II and 83% of grade III meningiomas tested, but was not different between grades. RT-qPCR revealed no difference in the mRNA expression of APOBEC3B between grades. Sequencing revealed no elevated levels of the C>T mutations that are characteristic of APOBEC3B editing of genomic DNA. Treatment with cerebrospinal fluid and PDGF-BB had no effect on APOBEC3B protein expression in the leptomeningeal or meningioma cells. These findings suggest that the mutations associated with increased APOBEC3B expression may not be central to the pathogenesis of meningiomas.
Introduction
Recent studies have indicated that normal cellular enzymatic activity may contribute to the genomic changes associated with various neoplasias (1) (2) (3) . Apolipoprotein B mRNA-editing enzymes (APOBEC) comprise a family of enzymes that protect immune function and are involved in mRNA editing; their cytosine deaminase activity may also induce base substitutions in the genomes of malignancies (1, 2) .
APOBEC3B is a cytosine deaminase that is responsible for the deamination of cytosines in the genome of host cells, producing cytosine to thymidine mutations (2) . Recently studies have found that APOBEC3B is overexpressed in several types of malignancy, resulting in clusters of C>T mutations that are considered to be the signature of APOBEC mutation in tumors. Analysis of whole-genome and whole-exome sequencing data from various types of malignancy have implicated APOBEC members in mRNA editing and the production of cytosine mutation clusters in the development or progression of numerous neoplastic processes, encompassing lung, breast, hepatic and hematopoietic malignancies (4) (5) (6) (7) (8) (9) . APOBEC3B overexpression has been identified in breast, head and neck cancers (7) (8) (9) (10) . Although APOBEC3B expression has not been studied in meningiomas, the presence of C>T point mutations in some meningioma cases raises the possibility that APOBEC3B may participate in the pathogenesis of at least a subset of meningiomas (11) .
The present study evaluated APOBEC3B expression in addition to mutations in a series of normal leptomeninges, and World Health Organization (WHO) grade I, II and III meningiomas. Human cerebrospinal fluid from patients without neurological disease. As meningiomas are bathed in cerebrospinal fluid, which has been demonstrated to affect meningioma cell proliferation (13) , its effects on APOBEC3B were evaluated in the current study. Remnant, discarded lumbar cerebrospinal fluid was collected at the University of Rochester Medical Center and sent to the Department of Pathology between March 2009 and September 2012. Samples from patients who were found to be free of neurological disease, and who had a cytopathological analysis showing no erythrocytes or increased lymphocytes were classified as 'normal'. In patients who had cerebrospinal fluid collected as part of a staging protocol for a peripheral lymphoma, only cerebrospinal fluid from those with no lymphoma cells or abnormal numbers of lymphocytes by cytology and no neurological disease were used. In some cases, due to limited volumes, multiple samples were combined to achieve quantities sufficient for the experimental design. Cerebrospinal fluid samples were initially frozen at -17˚C prior to storage at -80˚C. Quantitative polymerase chain reaction (qPCR) for APOBEC3B was performed in triplicate using primers for APOBEC3B (forward, 5'-GAC CCT TTG GTC CTT CGAC-3'; reverse, 5'-GCA CAG CCC CAG GAG AAG-3') and the RPL13A control gene (forward 5'-AGA TGG CGG AGG TGC AG-3' and reverse 5'-GCC AGA AAT GTT GAT GCC TT-3'). The qPCR reaction mixture was composed of 1X iTaq Universal SYBR Green Supermix (Bio-Rad Laboratories, Inc.), 1 µM primer mix, and 4.9 µl of diluted cDNA in a total volume of 10 µl. Reactions were performed on the Bio-Rad CFX Connect Real-Time System using the default protocol CFX_2StepAmp+Melt, as follows: 95˚C for 3 min, followed by 40 cycles of 95˚C for 10 sec and 55˚C for 30 sec, and 95˚C for 10 sec. Data was collected using Bio-Rad CFX Manager 3.0 software (Bio-Rad Laboratories, Inc.). Relative quantification was performed using the 2 -ΔΔCq calculation method (14) .
Materials and methods

Human
Sequencing of APOBEC3B DNA in leptomeningeal tissue and meningioma tumors. DNA was isolated from frozen meningioma tissue using the Qiagen DNeasy Blood and Tissue Kit according to the manufacturer's guidelines, and stored at -80˚C. Sequencing was performed using a TruSeq Amplicon-Cancer Panel (Illumina, Inc., San Diego, CA, USA). Sequences and controls were compared against the known sequence.
Effects of platelet-derived growth factor-BB (PDGF-BB)
and cerebrospinal fluid on APOBEC3B protein expression. PDGF-BB and cerebrospinal fluid were previously demonstrated to influence leptomeningeal and meningioma cell proliferation (13) . Consequently, confluent cells from 3 primary fetal leptomeningeal cell cultures (gestational ages 20, 20 and 22 weeks), 2 WHO grade I and 2 WHO grade II primary meningioma cultures were serum-deprived overnight prior to treatment with serum-free DMEM, DMEM containing 10 ng/ml PDGF-BB, or pooled cerebrospinal fluid from patients, for 72 h. Lysates of the cells were then analyzed by western blotting, as follows. Meningioma lysates were homogenized in RIPA Lysis Buffer as described above. Following quantification of protein concentrations, 10 µg protein from each sample was loaded and run on a 7.5% acrylamide gel, then transferred to a 0.45-µm nitrocellulose membrane. The membrane was blocked for 1 h in 5% milk in Tris-Cl buffer with Tween 20, then reacted with the affinity-purified primary antibody overnight at 4˚C. This was followed by horseradish peroxidase-conjugated secondary antibody treatment. Detection was achieved with Western Lightning reagent (PerkinElmer, Inc., Waltham, MA, USA) on Kodak Xomat film. All western blots were subsequently repeated and quantified with Clarity Western ECL substrate (Bio-Rad Laboratories, Inc.) and Chemidoc software.
Results
APOBEC3B protein expression in leptomeninges and meningioma.
As shown in Fig. 1A , APOBEC3B was detected in the 16-, 17-, 20-, 22-and 23-week fetal and the adult leptomeningeal tissues. In the meningiomas, APOBEC3B was detected in 15 of 17 WHO grade I meningiomas (Fig 1B) . APOBEC3B was also detected in all 17 WHO grade II and 5 of 6 grade III tumors (Fig. 1B) .
Analysis of APOBEC3B mRNA in leptomeningeal tissue and meningioma tumors. qPCR was used to assess the expression levels of APOBEC3B, which were calculated relative to RPL13A for each specimen and normalized to expression in the adult meninges specimen. The relative APOBEC3B expression in fetal leptomeninges was 4-fold higher than that in normal adult tissue. APOBEC3B expression levels tended to be lower in grade III compared to grade I and II tumors, but were not markedly different (Fig. 2) . Additionally, in the WHO grade I and II meningioma cell cultures, these treatments had no effect (data not shown).
Discussion
APOBEC3B mRNA has been demonstrated to be overexpressed in certain epithelial malignancies, including a high proportion of breast, ovarian and lung carcinomas (5, 15, 16) , and has been shown to promote the development of malignancy (7) (8) (9) (10) . This is considered to be due to an increased transition from dC to dT and the resultant increased mutation frequency (5). These mutations were commonly found in oncogenes transcribed in tumor cells (17) ; for example, in lymphoma cell lines, overexpression of APOBEC3B produced an increase in dC to dT mutations in c-Myc (18) . In the present study, it was shown that APOBEC3B was present in all of the fetal leptomeninges, 88% of WHO grade I, 100% of grade II and 83% of grade III meningiomas tested, without differences between grades. PCR revealed no overexpression and sequencing revealed no mutation in APOBEC3B. These findings suggest that, in contrast to several other epithelial malignancies, the overexpression and C>T point mutations in the genome of meningiomas may not be critical to the pathogenesis of meningiomas. Nonetheless, the number of WHO grade III meningiomas available for analysis was limited, and we therefore cannot exclude the possibility that some subtypes of grade III meningiomas may exhibit overexpression. High APOBEC expression was identified in a few, particularly WHO grade II, meningiomas. Like the majority of meningiomas in this study, these were from tumors in female patients. However, these were distributed amongst histological subtypes with no distinct predilection for site. Nonetheless, the number from any location was limited.
Based on embryological studies, other deaminase DNA-editing enzyme families may be more important in the pathogenesis of meningioma. For example, while the the APOBEC family is important in embryogenesis, the adenosine deaminase acting on RNA (ADAR) family is more important in brain development (19) . Nonetheless, the current study identified no definite changes in APOBEC expression among the meningiomas in this series.
